Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovarian cancer patients in Southern Poland

doi:10.1186/s13053-016-0046-5

Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovarian cancer patients in Southern Poland

Communities & Collections

pcg.skipToMenu

Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovarian cancer patients in Southern Poland

View Usage Statistics

Bibliographic description

punktacja MEiN [2016 A]: 15

title:	Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovarian cancer patients in Southern Poland
author:	Wojcik P., Jasiowka M., Strycharz E., Sobol M., Hodorowicz-Zaniewska Diana , Skotnicki P., Byrski T., Blecharz P., Marczyk E., Cedrych I., Jakubowicz J., Lubiński J., Sopik V., Narod S., Pierzchalski Piotr
journal title:	Hereditary Cancer in Clinical Practice
volume:	14
date of publication :	2016
article ID:	5
ISSN:	1731-2302
eISSN:	1897-4287
DOI:	10.1186/s13053-016-0046-5
language:	English
journal language:	English
abstract in English:	Background Mutations in the BRCA1, BRCA2 and PALB2 genes are well-established risk factors for the development of breast and/or ovarian cancer. The frequency and spectrum of mutations in these genes has not yet been examined in the population of Southern Poland. Methods We examined the entire coding sequences of the BRCA1 and BRCA2 genes and genotyped a recurrent mutation of the PALB2 gene (c.509_510delGA) in 121 women with familial and/or early-onset breast or ovarian cancer from Southern Poland. Results A BRCA1 mutation was identified in 11 of 121 patients (9.1 %) and a BRCA2 mutation was identified in 10 of 121 patients (8.3 %). Two founder mutations of BRCA1 accounted for 91 % of all BRCA1 mutation carriers (c.5266dupC was identified in six patients and c.181 T > G was identified in four patients). Three of the seven different BRCA2 mutations were detected in two patients each (c.9371A > T, c.9403delC and c.1310_1313delAAGA). Three mutations have not been previously reported in the Polish population (BRCA1 c.3531delT, BRCA2 c.1310_1313delAAGA and BRCA2 c.9027delT). The recurrent PALB2 mutation c.509_510delGA was identified in two patients (1.7 %). Conclusions The standard panel of BRCA1 founder mutations is sufficiently sensitive for the identification of BRCA1 mutation carriers in Southern Poland. The BRCA2 mutations c.9371A > T and c.9403delC as well as the PALB2 mutation c.509_510delGA should be included in the testing panel for this population.
keywords in English:	BRCA1, BRCA2, PALB2, breast cancer, ovarian cancer
departmental parameterization:	15
affiliation:	Wydział Lekarski : Klinika Chirurgii Ogólnej, Onkologicznej i Gastroenterologicznej, Wydział Nauk o Zdrowiu : Instytut Fizjoterapii
type:	journal article
subtype:	academic paper